

### This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Metastatic cancer	miR-373; miR-520c; CD44	<i>In vitro</i> and <i>in vivo</i> studies suggest that miR-373 and miR-520c could be used as targets to treat metastatic cancers or as markers of metastasis risk. The two miRNAs promoted tumor cell migration <i>in vitro</i> and tumor metastasis in immunodeficient mice. Suppression of CD44 was required for miR-373 to promote metastasis. Going forward, increased levels of these miRNAs might be used to predict metastatic risk in patients. Arius Research Inc. has an anti-CD44 antibody, AR001 (ARH460-16-2), in preclinical testing to treat cancer.	Patent applications filed; available for licensing	Huang, Q. <i>et al. Nat. Cell Biol.</i> ; published online Jan. 13, 2008; doi:10.1038/ncb1681 <b>Contact:</b> Reuven Agami, The Netherlands Cancer Institute, Amsterdam, The Netherlands e-mail: <a href="mailto:r.agami@nki.nl">r.agami@nki.nl</a> <b>Contact:</b> Qihong Huang, The Wistar Institute, Philadelphia, Pa. e-mail: <a href="mailto:qhuang@wistar.org">qhuang@wistar.org</a>